sponsored
PatientsVille.com Logo

PatientsVille

Parcopa Medical Research Studies

Up-to-date List of Parcopa Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Parcopa Medical Research Studies

Rank Status Study
1 Not yet recruiting Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects
Condition: Acute Pain
Interventions: Drug: Naproxen;   Drug: Sinemet;   Drug: Placebo
Outcome Measure: VAS pain scale
2 Recruiting Antipsychotic Augmentation With L-Dopa
Condition: Schizophrenia
Intervention: Drug: levodopa/carbidopa (generic version of Sinemet)
Outcome Measures: SANS - Schedule for the Assessment of Negative Symptoms;   MATRICS-Consensus Cognitive Battery;   BPRS - Brief Psychotic Rating Scale;   SAPS - Schedule for the Assessment of Positive Symptoms;   NIMH-MATRICS Brief Negative Symptoms Scale;   CGI-S - Clinical Global Impression - Severity Scale;   QLS - Quality of Life Scale;   CDS - Calgary Depression Scale;   SAS - Simpson Angus Scale for Extrapyramidal Symptoms;   BARS - Barnes Akathisia Rating Scales;   AIMS - Abnormal Involuntary Movement Scale;   UKU - Udvalg for Kliniske Undersogelses;   LUNSERS - Liverpool University Neuroleptic Side-Effect Rating Scale;   BIS-11 - Barrett Impulsivity Scale;   Y-BOCS - Yale-Brown Obsessive Compulsive Scale;   DAI - Drug Attitude Inventory;   fMRI - Functional Magnetic Resonance Imaging;   SWN - Subjective Well-Being on Neuroleptics Scale
3 Recruiting A Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel for the Treatment of Non-motor Symptoms in Subjects With Advanced Parkinson's Disease
Condition: Advanced Parkinson's Disease
Intervention: Drug: Levodopa-Carbidopa Intestinal Gel
Outcome Measures: To assess changes in non-motor symptoms using Non-Motor Symptom Scale;   Number of subjects who use health resources;   Number of subjects who have Adverse Events;   To assess changes in motor symptoms using United Parkinson's Disease Rating Scale;   To assess improvements in cognition using neurocognition assessments: Spatial Working Memory;   To assess changes in quality of life through: Parkinson's Disease Questionnaire-39 Item;   To assess changes in quality of life through: Patient Global Impression of Change;   To assess changes in quality of life through: Treatment Satisfaction Question;   To assess changes in quality of life through: Health-Related Productivity Questionnaire;   To assess changes in motor symptoms using Parkinson's Disease Diary
4 Recruiting Levodopa Carbidopa Intestinal Gel Home Titration Using Telemedicine: Evaluation of Use of Resources
Condition: Parkinson's Disease
Intervention:
Outcome Measures: Resource use;   Total time for titration;   Patient's daily free time;   Technical feasibility;   Health care utilization;   Clinical Global Impression - Improvement;   Experience of Levodopa Carbidopa Intestinal Gelhome titration using Telemedicine
5 Recruiting Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
Condition: Cocaine Dependence
Interventions: Drug: levodopa carbidopa and entacapone (LCE);   Drug: Placebo
Outcome Measure: Cocaine urine toxicology
6 Recruiting Erythromycin in Parkinson's Disease
Conditions: Parkinson's Disease;   Levodopa
Intervention: Drug: Erythromycin
Outcome Measures: Change in gastric emptying time as measured by Smart pill;   Change in Area under the Curve 0-4 hours for plasma levodopa after a single dose of sinemet;   Change in Cmax for plasma levodopa;   change in latency to "on" following a single dose of Sinemet;   Change in total duration of "on" time in minutes from a single dose of Sinemet;   Change in motor function and dyskinesia
7 Recruiting Vision Response to Dopamine Replacement
Conditions: Albinism;   Oculocutaneous Albinism
Intervention: Drug: Levodopa/carbidopa
Outcome Measures: Visual Acuity Improvement;   Retinal Function
8 Recruiting Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse
Condition: Cocaine Dependence
Intervention: Drug: levodopa/carbidopa 400/100 BID
Outcome Measure: Cocaine treatment outcome
9 Recruiting Neurobiological Principles Applied to the Rehabilitation of Stroke Patients
Condition: Stroke
Interventions: Drug: Sinemet, ritalin, amphetamine, and placebo;   Device: Transcranial magnetic stimulation (TMS);   Other: Combined drug treatment and TMS
Outcome Measures: Specific Aim 1: Increases of noradrenergic, dopaminergic and serotonergic transmission will enhance use-dependent plasticity in intact M1.;   Specific Aim 2: M1 Stimulation is most effective in increasing use-dependent plasticity when the stimulus occurs within 50 ms of M1 pyramidal tract neuron discharge with 0.1 to 0.3 Hx frequency (reminiscent of settings used for Hebbian-type stimulation).;   Specific Aim 3: Hebbian-type stimulation of M1 and increase of monoaminergic transmission facilitates training induced changes of motor representation in the lesioned hemisphere of patients post-stroke.
10 Not yet recruiting Effect of L-dopa In Subacute Back Pain Population
Condition: Sub-acute Back Pain
Interventions: Drug: Naproxen;   Drug: Carbidopa/Levodopa;   Drug: Placebo
Outcome Measure: VAS pain scale
11 Unknown  Substance Abuse Pre-Treatment Screening Study
Conditions: Cocaine Abuse;   Cocaine Dependence;   Opiate Dependence;   Alcohol Dependence;   Substance Abuse
Interventions: Drug: modafinil;   Drug: d-amphetamine;   Drug: L-Dopa;   Drug: Naltrexone
Outcome Measures: Urine Toxicology;   Demographics
12 Unknown  Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study
Condition: Dystonic Cerebral Palsy
Interventions: Drug: L- DOPA;   Drug: placebo
Outcome Measures: QUEST quality of upper extremity skills test score before and after treatment;   box and blocks, 9 hole pegs, pronation/ supination, finger sequencing
13 Recruiting Treatment of Orthostatic Hypotension in Autonomic Failure
Conditions: Autonomic Failure;   Orthostatic Hypotension
Interventions: Drug: Atomoxetine;   Drug: Acarbose;   Drug: Pyridostigmine Bromide;   Drug: Yohimbine;   Drug: Midodrine HCl;   Drug: placebo;   Drug: Modafinil;   Drug: Octreotide;   Other: water intake;   Drug: Diphenhydramine Hydrochloride;   Drug: Ranitidine HCL;   Drug: Tranylcypromine;   Drug: Ergotamine/ Caffeine;   Drug: Celecoxib;   Drug: Pseudoephedrine;   Drug: Methylphenidate;   Drug: Indomethacin;   Drug: Ibuprofen;   Drug: Oxymetazoline 0.05% nasal solution;   Dietary Supplement: Bovril;   Drug: Acetazolamide;   Drug: Rivastigmine tartrate;   Drug: Carbidopa/levodopa;   Device: Inflatable abdominal binder;   Device: inflatable abdominal binder (sham)
Outcome Measures: Increase in seated systolic blood pressure 1-hr post drug compared to baseline.;   Increase in standing time 1-hr post drug compared to baseline
14 Recruiting Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury
Condition: Spinal Cord Injury
Intervention: Drug: SPINALON (buspirone + levodopa + cardidopa)
Outcome Measures: Heart rate;   Tolerability of common AEs;   Pharmacokinetics;   Blood pressure;   Respiration rate;   Oxygen saturation;   Temperature;   Change in hematology and biochemistry laboratory parameters;   Occurrence of rhythmic leg EMGs
15 Recruiting A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
Condition: Advanced Parkinson's Disease
Intervention: Drug: ABT-SLV187
Outcome Measures: Change in the mean daily "Off" time (hours) as measured by the Parkinson's Disease (PD) Diary©;   Change in PD Diary mean daily "On" time without troublesome dyskinesia ("On" time without dyskinesia or with non-troublesome dyskinesia) or "On" time with troublesome dyskinesia;   Change in Clinical Global Impression of Change (CGI-C) scores;   Change in Patient Global Impression of Change (PGIC) scores;   Change in the Unified Parkinson's Disease Rating Scale (UPDRS) score;   Change in the Parkinson's Disease Questionnaire-39 (PDQ-39) scores;   Physical Exam;   Change in Neurological Exam;   Change in Vital Signs;   Change in Clinical Labs;   Change in 12-lead electrocardiogram (ECG);   Number of Participants with Adverse Events
16 Unknown  Medications for Stopping Cocaine Dependence and Preventing Relapse
Conditions: Cocaine Abuse;   Cocaine-Related Disorders
Interventions: Drug: Naltrexone;   Drug: Modafinil;   Drug: Levodopa/Carbidopa;   Drug: Placebo
Outcome Measure: Confirmed abstinence from cocaine

These studies may lead to new treatments and are adding insight into Parcopa etiology and treatment.

A major focus of Parcopa research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Parcopa